

Date: 26/06/2019

FREEDOM OF INFORMATION REQUEST FOI/014864 - Multiple myeloma and other cancers

I am writing to you today to request the following information regarding Cancer Treatments at your organisation.

1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which. - Yes

2. If yes, then how many MM patients, have been treated in the past 6 months with the following;
- The Pharmacy database does not identify drugs against patient disease.

3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line.

- The Pharmacy database does not identify drugs against patient disease

4. Does your trust treat adult/paediatric primary immune thrombocytopenia patients [ITP] ? - if you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which. - Yes

5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following; - The Pharmacy database does not identify drugs against patient disease

Eltrombopag [Revolade]

Romiplostim [Nplate]

6. At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient.

- The Trust would treat in line with NICE guidelines and funding

7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases?

- The Pharmacy database does not identify drugs against patient disease

7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy - N/A

Eltrombopag [Revolade]

Romiplostim [Nplate]

7b. Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation - N/A

Eltrombopag [Revolade]

Romiplostim [Nplate]

7c. Chemotherapy induced thrombocytopenia (CIT) - N/A

Eltrombopag [Revolade]

Romiplostim [Nplate]

7d. Myelodysplastic syndromes (MDS) - N/A

Eltrombopag [Revolade]

Romiplostim [Nplate]

8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

- Using admitted patient care (APC) as our data source, over the past 6 months (Nov-18 to Apr-19) we have had 15 patients discharged from an inpatient or day case hospital spell where the primary diagnosis was C911 (CLL). This does not mean that the patient had any specific treatment for the cancer, just that they had a stay in hospital.

9. If possible how many CLL patients treated were new to therapy in the past 3 months?

- We cannot tell from APC whether the spell was a treatment for CLL, or whether it was the first treatment for CLL.

10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following

- The Pharmacy database does not identify drugs against patient disease